148 related articles for article (PubMed ID: 18986283)
1. What can we learn from the time course of untreated and partially treated community-onset Streptococcus pneumoniae pneumonia? A clinical perspective on superiority and noninferiority trial designs for mild community-acquired pneumonia.
File TM; Schentag JJ
Clin Infect Dis; 2008 Dec; 47 Suppl 3():S157-65. PubMed ID: 18986283
[TBL] [Abstract][Full Text] [Related]
2. Clinical trial design for mild-to-moderate community-acquired pneumonia--an industry perspective.
Echols RM; Tillotson GS; Song JX; Tosiello RL
Clin Infect Dis; 2008 Dec; 47 Suppl 3():S166-75. PubMed ID: 18986284
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics-pharmacodynamics of quinolones against Streptococcus pneumoniae in patients with community-acquired pneumonia.
Bhavnani SM; Forrest A; Hammel JP; Drusano GL; Rubino CM; Ambrose PG
Diagn Microbiol Infect Dis; 2008 Sep; 62(1):99-101. PubMed ID: 18583085
[TBL] [Abstract][Full Text] [Related]
4. A disease model descriptive of progression between chronic obstructive pulmonary disease exacerbations and community-acquired pneumonia: roles for underlying lung disease and the pharmacokinetics/pharmacodynamics of the antibiotic.
File TM; Monte SV; Schentag JJ; Paladino JA; Klugman KP; Lavin B; Yu VL; Singer ME; Adelman MH
Int J Antimicrob Agents; 2009 Jan; 33(1):58-64. PubMed ID: 18835762
[TBL] [Abstract][Full Text] [Related]
5. Clinical experience in the management of community-acquired pneumonia: lessons from the use of fluoroquinolones.
Carratalá J; Martín-Herrero JE; Mykietiuk A; García-Rey C
Clin Microbiol Infect; 2006 May; 12 Suppl 3():2-11. PubMed ID: 16669924
[TBL] [Abstract][Full Text] [Related]
6. Scenario 1: a patient with mild community-acquired pneumonia--introduction to clinical trial design issues.
Gilbert DN
Clin Infect Dis; 2008 Dec; 47 Suppl 3():S121-2. PubMed ID: 18986276
[TBL] [Abstract][Full Text] [Related]
7. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study.
File TM; Mandell LA; Tillotson G; Kostov K; Georgiev O
J Antimicrob Chemother; 2007 Jul; 60(1):112-20. PubMed ID: 17537866
[TBL] [Abstract][Full Text] [Related]
8. Streptococcus pneumoniae: does antimicrobial resistance matter?
Lynch JP; Zhanel GG
Semin Respir Crit Care Med; 2009 Apr; 30(2):210-38. PubMed ID: 19296420
[TBL] [Abstract][Full Text] [Related]
9. Placebo-controlled trials of treatments for community-acquired pneumonia: review of the literature and discussion of feasibility and potential value.
Murphy TF
Clin Infect Dis; 2008 Dec; 47 Suppl 3():S145-9. PubMed ID: 18986281
[TBL] [Abstract][Full Text] [Related]
10. [Acute community-acquired pneumonia. A review of clinical trials].
Chidiac C
Med Mal Infect; 2006; 36(11-12):650-66. PubMed ID: 16876363
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of community-acquired pneumonia--treatment].
Andersen LV; Brock B; Jakobsen P; Nielsen LP
Ugeskr Laeger; 2008 Jan; 170(3):127-30. PubMed ID: 18208726
[TBL] [Abstract][Full Text] [Related]
12. Unique considerations in the evaluation of antibacterials in clinical trials for pediatric community-acquired pneumonia.
Bradley JS; McCracken GH
Clin Infect Dis; 2008 Dec; 47 Suppl 3():S241-8. PubMed ID: 18986297
[TBL] [Abstract][Full Text] [Related]
13. Historical and regulatory perspectives on the treatment effect of antibacterial drugs for community-acquired pneumonia.
Singer M; Nambiar S; Valappil T; Higgins K; Gitterman S
Clin Infect Dis; 2008 Dec; 47 Suppl 3():S216-24. PubMed ID: 18986293
[TBL] [Abstract][Full Text] [Related]
14. Clinical efficacy of newer agents in short-duration therapy for community-acquired pneumonia.
File TM
Clin Infect Dis; 2004 Sep; 39 Suppl 3():S159-64. PubMed ID: 15546111
[TBL] [Abstract][Full Text] [Related]
15. Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults.
Hak E; Grobbee DE; Sanders EA; Verheij TJ; Bolkenbaas M; Huijts SM; Gruber WC; Tansey S; McDonough A; Thoma B; Patterson S; van Alphen AJ; Bonten MJ
Neth J Med; 2008 Oct; 66(9):378-83. PubMed ID: 18990781
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes of bacteremic pneumococcal pneumonia in the era of antibiotic resistance.
Moroney JF; Fiore AE; Harrison LH; Patterson JE; Farley MM; Jorgensen JH; Phelan M; Facklam RR; Cetron MS; Breiman RF; Kolczak M; Schuchat A
Clin Infect Dis; 2001 Sep; 33(6):797-805. PubMed ID: 11512085
[TBL] [Abstract][Full Text] [Related]
17. Antimicrobial resistance and treatment of community-acquired pneumonia.
Mandell LA
Clin Chest Med; 2005 Mar; 26(1):57-64. PubMed ID: 15802166
[TBL] [Abstract][Full Text] [Related]
18. Pneumonia in older persons.
Loeb M
Clin Infect Dis; 2003 Nov; 37(10):1335-9. PubMed ID: 14583867
[TBL] [Abstract][Full Text] [Related]
19. Community-acquired pneumonia: new management strategies for evolving pathogens and antimicrobial susceptibilities.
Klugman KP; Low DE; Metlay J; Pechere JC; Weiss K
Int J Antimicrob Agents; 2004 Nov; 24(5):411-22. PubMed ID: 15519470
[TBL] [Abstract][Full Text] [Related]
20. Severe community-acquired pneumonia in adults: current antimicrobial chemotherapy.
Niven DJ; Laupland KB
Expert Rev Anti Infect Ther; 2009 Feb; 7(1):69-81. PubMed ID: 19622058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
